Success Metrics

Clinical Success Rate
81.1%

Based on 30 completed trials

Completion Rate
81%(30/37)
Active Trials
2(4%)
Results Posted
47%(14 trials)
Terminated
7(15%)

Phase Distribution

Ph phase_2
18
38%
Ph phase_1
17
36%
Ph not_applicable
2
4%
Ph phase_3
3
6%

Phase Distribution

17

Early Stage

18

Mid Stage

3

Late Stage

Phase Distribution40 total trials
Phase 1Safety & dosage
17(42.5%)
Phase 2Efficacy & side effects
18(45.0%)
Phase 3Large-scale testing
3(7.5%)
N/ANon-phased studies
2(5.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

76.9%

30 of 39 finished

Non-Completion Rate

23.1%

9 ended early

Currently Active

2

trials recruiting

Total Trials

47

all time

Status Distribution
Active(2)
Completed(30)
Terminated(9)
Other(6)

Detailed Status

Completed30
Terminated7
unknown6
Active, not recruiting2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
47
Active
2
Success Rate
81.1%
Most Advanced
Phase 3

Trials by Phase

Phase 117 (42.5%)
Phase 218 (45.0%)
Phase 33 (7.5%)
N/A2 (5.0%)

Trials by Status

active_not_recruiting24%
completed3064%
terminated715%
unknown613%
withdrawn24%

Recent Activity

Clinical Trials (47)

Showing 20 of 47 trialsScroll for more
NCT01479842Phase 1

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Active Not Recruiting
NCT01196936Phase 2

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Active Not Recruiting
NCT01206465Phase 1

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

Completed
NCT00611351Phase 2

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Completed
NCT00665457Phase 2

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Terminated
NCT01267812Phase 2

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Completed
NCT00981162Phase 1

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Completed
NCT00936832Phase 2

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Withdrawn
NCT01192815Phase 2

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Terminated
NCT00735917Phase 2

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Completed
NCT01208064Phase 2

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

Terminated
NCT01557959Phase 2

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed
NCT00770471Phase 1

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
NCT01129193Phase 1

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Completed
NCT01705106Phase 1

Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies

Terminated
NCT00873366

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

Terminated
NCT00445744Not Applicable

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Completed
NCT00764322Phase 2

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

Completed
NCT01185886

Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown
NCT01599832Not Applicable

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

Terminated

Drug Details

Intervention Type
OTHER
Total Trials
47